The effect of metformin on urate metabolism: Findings from observational and Mendelian randomization analyses

Abstract

Aim: To evaluate the effect of metformin on urate metabolism.

Materials and methods: Using the UK Biobank, we first performed association analyses of metformin use with urate levels, risk of hyperuricaemia and incident gout in patients with diabetes. To explore the causal effect of metformin on urate and gout, we identified genetic variants proxying the glycated haemoglobin (HbA1c)-lowering effect of metformin targets and conducted a two-sample Mendelian randomization (MR) utilizing the urate and gout genetic summary-level data from the CKDGen (n = 288 649) and the FinnGen cohort. We conducted two-step MR to explore the mediation effect of body mass index and systolic blood pressure. We also performed non-linear MR in the UK Biobank (n = 414 055) to show the results across HbA1c levels.

Results: In 18 776 patients with type 2 diabetes in UK Biobank, metformin use was associated with decreased urate [β = -4.3 μmol/L, 95% confidence interval (CI) -7.0, -1.7, p = .001] and reduced hyperuricaemia risk (odds ratio = 0.87, 95% CI 0.79, 0.96, p = .004), but not gout. Genetically proxied averaged HbA1c-lowering effects of metformin targets, equivalent to a 0.62% reduction in HbA1c, was associated with reduced urate (β = -12.5 μmol/L, 95% CI -21.4, -4.2, p = .004). Body mass index significantly mediated this association (proportion mediated = 33.0%, p = .002). Non-linear MR results suggest a linear trend of the effect of metformin on urate reduction across various HbA1c levels.

Conclusions: The effect of metformin may reduce urate levels but not incident gout in the general population.

Keywords: Mendelian randomization analysis; diabetes mellitus; drug repositioning; gout; hyperuricaemia; metformin; type 2.